Litigation Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Docket		Date Filed	2016-07-07
Court	District Court, D. Delaware	Date Terminated	2019-01-10
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To
Patents	9,259,421
Link to Docket	External link to docket

Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-07-07				External link to document
2016-07-07	28		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,259,421 B2. (Attachments: #…2016 10 January 2019 1:16-cv-00582 830 Patent Defendant District Court, D. Delaware	External link to document
2016-07-07	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,259,421 B2. (cna) (Entered:…2016 10 January 2019 1:16-cv-00582 830 Patent Defendant District Court, D. Delaware	External link to document

Orexo AB v. Actavis Elizabeth LLC, 1:16-cv-00582: Litigation Summary and Patent Analysis

Last updated: August 9, 2026

Orexo prevailed against Actavis in patent litigation concerning Zubsolv, a sublingual buprenorphine/naloxone tablet used for opioid-dependence treatment. The case centered on U.S. Patent No. 8,778,377, which covers aspects of Orexo's rapidly dissolving tablet formulation. The Federal Circuit affirmed the district court's judgment that the asserted claims were not invalid for obviousness and that Actavis's ANDA product infringed the patent. [1]

What drug and patent were at issue in Orexo v. Actavis?

The dispute involved Zubsolv, Orexo's buprenorphine hydrochloride/naloxone hydrochloride sublingual tablet. Zubsolv is approved under FDA NDA No. 204442 for maintenance treatment of opioid dependence as part of a complete treatment program that includes counseling and psychosocial support. [2]

The principal patent was U.S. Patent No. 8,778,377, assigned to Orexo AB. The patent covers pharmaceutical compositions containing buprenorphine and naloxone in a sublingual tablet designed to provide rapid dissolution and effective delivery.

Item	Details
Plaintiff	Orexo AB
Defendant	Actavis Elizabeth LLC, an affiliate of Actavis/Allergan
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:16-cv-00582
Product	Zubsolv
Active ingredients	Buprenorphine hydrochloride and naloxone hydrochloride
Dosage form	Sublingual tablet
Principal patent	U.S. Patent No. 8,778,377
ANDA pathway	Abbreviated New Drug Application with Paragraph IV certification
Federal Circuit decision	903 F.3d 1265 (Fed. Cir. 2018)

What patents protected Zubsolv in the Actavis litigation?

The case principally concerned the '377 patent. The asserted claims addressed the composition and performance of the sublingual dosage form rather than merely the active ingredients themselves.

The patent estate's commercial value came from formulation characteristics that differentiated Zubsolv from earlier buprenorphine/naloxone products, including:

• Rapid dissolution under the tongue.
• Delivery of buprenorphine and naloxone in a defined dosage-form architecture.
• Use of excipients and formulation features designed to support bioavailability.
• Reduced tablet size and improved administration characteristics compared with certain earlier products.

The litigation did not primarily concern a new chemical entity patent for buprenorphine or naloxone. Those active ingredients were known before Zubsolv. Orexo's position depended on the patentability of the formulation and delivery system.

The '377 patent was listed in the FDA Orange Book for Zubsolv. Public Orange Book records identify patent protection extending beyond the original 2013 approval period. [3]

What formulation features were legally important?

The Federal Circuit's analysis focused on whether a skilled artisan would have been motivated to modify known buprenorphine/naloxone formulations to arrive at the claimed Zubsolv formulation, and whether the prior art provided a reasonable expectation of success.

Orexo argued that the claimed formulation achieved a combination of properties that was not predictable from the prior art. Actavis relied on earlier disclosures involving buprenorphine, naloxone, sublingual delivery, tablet formulation, and formulation optimization.

The court treated the claimed combination as more than a routine aggregation of known ingredients. The litigation record placed weight on the formulation's rapid dissolution, bioavailability, and practical dosage-form characteristics.

What was Actavis's Paragraph IV challenge?

Actavis filed an ANDA seeking FDA approval for a generic version of Zubsolv. Its Paragraph IV certification alleged that the asserted claims of the '377 patent were invalid, unenforceable, or would not be infringed by the proposed generic product.

Under the Hatch-Waxman Act, the Paragraph IV certification created an artificial act of infringement under 35 U.S.C. § 271(e)(2). Orexo responded by filing the Delaware action in 2016.

The lawsuit triggered the statutory 30-month stay of FDA approval associated with a patent-infringement action based on a Paragraph IV certification, subject to earlier termination or other statutory events. The litigation therefore created a regulatory barrier to Actavis's generic approval while the patent case proceeded.

What did the district court decide?

The district court found that Actavis's ANDA product infringed the asserted claims and rejected Actavis's obviousness challenge. The district court's decision treated the asserted formulation claims as patentably distinct from the prior-art combinations advanced by Actavis.

The validity dispute turned on the familiar obviousness framework under 35 U.S.C. § 103:

1. The scope and content of the prior art.
2. Differences between the prior art and the asserted claims.
3. The level of ordinary skill in the art.
4. Objective indicia of nonobviousness.

The court considered commercial success, industry recognition, and the relationship between the claimed features and Zubsolv's commercial performance. Those factors supported Orexo, although the court did not treat commercial success as independently sufficient to establish validity.

What did the Federal Circuit decide in 903 F.3d 1265?

The Federal Circuit affirmed the district court's judgment. The appellate court held that the asserted claims of the '377 patent were not shown to be obvious and upheld the infringement determination. [1]

The decision is relevant for three reasons.

The prior art did not establish obviousness as a matter of law

Actavis identified prior-art references that disclosed elements of the claimed formulation. The Federal Circuit held that showing individual elements in separate references did not establish that a skilled artisan would have combined them in the claimed manner with a reasonable expectation of success.

The court rejected an analysis that reconstructed the invention from the finished product. The inquiry required evidence showing why the relevant skilled artisan would have selected the claimed formulation path.

Formulation optimization was not automatically routine

Actavis characterized the claimed changes as routine optimization. The Federal Circuit disagreed with treating the formulation variables as interchangeable or predictably adjustable.

The record showed that changes affecting dissolution, bioavailability, taste, tablet size, and drug-release behavior could produce competing results. That evidence supported the district court's conclusion that the claimed formulation was not an obvious design choice.

Objective indicia supported validity

The Federal Circuit accepted the district court's consideration of objective indicia of nonobviousness. Zubsolv's commercial success and the product's market acceptance were relevant because the evidence connected those results to the claimed formulation rather than to unrelated factors.

The decision did not establish that commercial success alone validates a pharmaceutical formulation patent. It confirmed that commercial evidence can strengthen a nonobviousness finding when a nexus exists between the patented features and the product's market performance.

What was the litigation outcome for Actavis's generic launch?

The Federal Circuit judgment prevented Actavis from relying on the challenged ANDA pathway while the '377 patent remained enforceable against the proposed product. The ruling preserved Orexo's patent-based barrier to the specific Actavis generic product at issue.

The reported Federal Circuit decision was an affirmance, not a remand for a new obviousness trial. The central issues of patent validity and infringement were therefore resolved in Orexo's favor at the appellate level.

The decision did not invalidate all possible generic versions of buprenorphine/naloxone sublingual tablets. A later generic applicant could pursue a different formulation, design around the asserted claims, challenge other listed patents, or rely on patent expiration and regulatory exclusivity dates.

How strong was Orexo's patent estate after the decision?

The '377 patent had meaningful litigation strength because it satisfied three conditions that often determine pharmaceutical patent value:

• It covered a commercially important formulation rather than only a narrow manufacturing step.
• The district court found infringement by the proposed generic product.
• The Federal Circuit affirmed the validity judgment.

The estate's strength was still narrower than a broad active-ingredient patent. Buprenorphine and naloxone were established compounds, and the principal barrier depended on the scope of the formulation claims and the similarity of a competing product.

Strength by patent category

Patent category	Relevance to Orexo v. Actavis	Assessment
Active-ingredient patent	Limited; ingredients were known	Weak as the central litigation theory
Formulation patent	Core basis of the case	Strong after Federal Circuit affirmance
Method-of-use patent	Not the principal issue	Secondary to the formulation claims
Manufacturing patent	Not the principal issue	Not dispositive in this action
Biologic patent	Not applicable	Zubsolv is a small-molecule combination product
Device or delivery-system patent	Sublingual delivery characteristics were relevant	Supporting technology category

What was the FDA and Orange Book status?

Zubsolv was approved by FDA in 2013 under NDA No. 204442. The product is a small-molecule combination drug, so biosimilar law does not apply. Generic competition proceeds through the ANDA process rather than the biosimilar pathway under the Public Health Service Act.

The Orange Book listing of the '377 patent provided the statutory foundation for Orexo's Hatch-Waxman lawsuit. The patent listing also required a generic applicant to address the patent through one of the statutory certification routes, including Paragraph IV.

Regulatory exclusivity and patent exclusivity were separate. Any new-drug exclusivity associated with Zubsolv's approval did not replace the patent protection. The commercial launch barrier in the Actavis case was principally patent-based.

Did the case involve biosimilar risk?

No. Zubsolv is not a biologic and is not subject to the biosimilar approval pathway. The relevant competitive risk was generic substitution through ANDAs.

The litigation nevertheless illustrates a broader pharmaceutical strategy: a sponsor can extend market protection after compound patents are unavailable by securing formulation patents that cover clinically and commercially relevant dosage-form characteristics.

Which companies were challenging Zubsolv?

Actavis Elizabeth LLC was the defendant in the reported litigation. The case should not be treated as a ruling against every potential Zubsolv generic applicant. Patent judgments are product-specific and depend on the ANDA formulation, asserted claims, infringement theory, and litigation record.

The decision increased the risk for generic applicants pursuing a formulation materially similar to Zubsolv. A design-around product with different excipients, particle characteristics, manufacturing parameters, or dissolution profile could present a different infringement analysis.

What revenue exposure did the litigation create?

The litigation protected Orexo's branded Zubsolv revenue from the specific Actavis ANDA product. The commercial exposure was substantial because generic entry for a branded opioid-dependence product can produce rapid price erosion and pharmacy substitution.

The case's value was higher than the value of a conventional single-patent dispute because:

• Zubsolv's commercial differentiation depended heavily on its formulation.
• The patent covered product characteristics likely to be replicated by a generic applicant.
• An adverse validity ruling could have accelerated generic competition.
• Federal Circuit affirmance reduced immediate invalidity risk for the asserted patent.

Public filings from Orexo provide the relevant company-level revenue and product-sales data for the applicable reporting periods. The reported case decision itself does not establish a damages award or a quantified revenue figure. [4]

What patent expiration and generic-entry scenarios applied?

The principal scenarios were:

Immediate entry after invalidity or noninfringement

This was the risk Actavis pursued through its Paragraph IV certification. The Federal Circuit decision materially reduced that risk by affirming Orexo's position.

Entry after patent expiry

A generic could enter after expiration of the relevant listed patent, subject to FDA approval and any remaining regulatory requirements. Patent expiration does not guarantee immediate commercial launch because approval timing, manufacturing readiness, and market strategy remain relevant.

Design-around entry

A generic applicant could seek approval for a formulation that avoids the asserted claims. This scenario would shift the dispute from validity to claim construction and infringement.

Settlement-based entry

A settlement could establish an agreed generic entry date and other commercial terms. The Federal Circuit opinion resolved the reported appellate issues, but the public appellate judgment does not itself establish a settlement date or a payment arrangement.

How does Orexo's estate compare with a compound-patent estate?

Orexo's position was narrower than an active-ingredient patent but stronger than a weak secondary patent because the formulation was central to the marketed product.

Factor	Zubsolv formulation estate	Broad compound estate
Scope	Product and dosage-form dependent	Often covers the active ingredient broadly
Design-around risk	Higher	Lower
Infringement proof	Requires product-specific analysis	Usually more direct
Obviousness risk	Often significant	Depends on compound discovery record
Commercial relevance	High when formulation drives product differentiation	High across dosage forms
Generic strategy	Formulation design-around or Paragraph IV	Invalidity, noninfringement, or expiration

Key Takeaways

• Orexo's case against Actavis concerned Zubsolv's buprenorphine/naloxone sublingual formulation.
• U.S. Patent No. 8,778,377 was the principal patent at issue.
• Actavis used a Paragraph IV certification to challenge the patent through the ANDA process.
• The district court found infringement and rejected the obviousness challenge.
• The Federal Circuit affirmed in Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018).
• The decision strengthened the enforceability of the asserted formulation claims against the challenged Actavis product.
• Biosimilar law was not relevant because Zubsolv is a small-molecule combination drug.
• The ruling did not eliminate all generic-entry routes, including design-around formulations and entry after patent expiry.

FAQs About Orexo v. Actavis and Zubsolv Patent Litigation

What was the case number for Orexo's Zubsolv litigation?

The district court case was Orexo AB v. Actavis Elizabeth LLC, No. 1:16-cv-00582, in the U.S. District Court for the District of Delaware.

What Federal Circuit citation applies to the case?

The appellate decision is Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018).

Was Zubsolv protected by a biologic exclusivity period?

No. Zubsolv is a small-molecule drug regulated through the NDA and ANDA framework, not the biologic and biosimilar framework.

Could Actavis market any buprenorphine/naloxone generic after the decision?

The decision did not prohibit every generic buprenorphine/naloxone product. It addressed the challenged ANDA product and the asserted patent claims.

Why did the Zubsolv formulation patent survive an obviousness challenge?

The courts found that the prior art did not adequately show why a skilled artisan would have selected the claimed combination of formulation characteristics with a reasonable expectation of success.

References

1. United States Court of Appeals for the Federal Circuit. (2018). Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265.
2. U.S. Food and Drug Administration. (2013). Zubsolv (buprenorphine hydrochloride and naloxone hydrochloride) sublingual tablets, NDA 204442. Drugs@FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Zubsolv. Orange Book.
4. Orexo AB. (2016-2018). Annual reports and regulatory filings.